New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Genmab A/S Sponsored ADR (GMAB) vs Moderna, Inc. (MRNA)

Genmab A/S Sponsored ADR and Moderna, Inc. are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $79.6B against $31.5B — 2.5× the size. Moderna, Inc. has negative trailing earnings, so its P/E is not meaningful; Genmab A/S Sponsored ADR trades at 43.0×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 19.8% against 13.1%. Genmab A/S Sponsored ADR has the higher net margin (17.0% vs −110.5%) and the higher return on invested capital (6.89% vs −35.1%). Across the 18 metrics below, Genmab A/S Sponsored ADR leads on 11 and Moderna, Inc. on 7.

Valuation

Metric GMAB MRNA Biotechnology median
P/E 42.98 n/m 8.49
P/S 7.22 30.99 8.56
P/B 4.90 11.44 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 29.78 n/m 0.69
EV/Sales 7.95 30.35 8.00
Earnings yield 2.33% (3.63%) (35.81%)
Free cash flow yield (20.53%) (2.61%) (25.41%)

Profitability

Metric GMAB MRNA Biotechnology median
Gross margin 92.60% 28.00% 70.18%
Operating margin 24.30% (116.04%) 0.00%
Net margin 16.97% (110.46%) 0.00%
Free cash flow margin (148.32%) (80.95%) 0.00%
Return on equity 12.07% (34.50%) (51.58%)
Return on assets 7.31% (21.79%) (45.91%)
Return on invested capital 6.89% (35.12%) 0.00%

Growth

Metric GMAB MRNA Biotechnology median
Revenue growth (TTM) 19.83% 13.13% 7.20%
EPS growth (last fiscal year) (12.50%) 21.77% 29.04%
Revenue growth, 5-year CAGR 19.15% 19.34% 9.54%
Net income growth, 5-year CAGR 5.73% — 0.00%

Health

Metric GMAB MRNA Biotechnology median
Debt to equity 0.79 0.52 0.00
Current ratio 2.45 3.62 4.79
Net debt to EBITDA 3.13 1.77 1.01

Dividend

Metric GMAB MRNA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GMAB MRNA Biotechnology median
Market cap 31.54b 79.59b 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack